Loading…
Fierce Drug Dev Forum 2019 has ended
avatar for Neil Dhawan

Neil Dhawan

TRILOGY SCIENCES
CEO
Neil is currently working on developing new chemical biology approaches to build small and large molecule oncology drugs. Neil previously co-founded Dual Therapeutics, a venture-backed biotechnology company creating novel multi-pathway inhibitors for cancer treatment. Neil co-invented and helped develop the lead drug program, which led to a collaboration deal with Bristol Myers Squibb valued at up to $225 million.